BeNeLuxBelgiumNetherlandsLuxembourg

Triple play ends

01.10.2011

Stockholm/Leiden/Barcelona – A complicated ménage a trois has come to an end: Swedish Orphan Biovitrum AB, Pharming Group N.V. and Esteve S.A. announced at the beginning of September that they were terminating a 2004 deal involving the drug Ruconest®. According to the terms of the agreement, Esteve received exclusive rights from Pharming to commercialise the hereditary angioedema treatment in Spain, Portugal, Andorra and Greece. Pharming has now granted those rights to Swedish Orphan, making it the sole distributor of the recombinant human complement 1 (C1) esterase inhibitor in all EU countries, Iceland, Norway, Switzerland, the Balkans, North Africa and the Middle East. Ruconest is approved for the indication in the EU. Further details were not disclosed.

BeNeLuxBelgiumNetherlandsLuxembourg

01.09.2011

New York - US-American investment firm OrbiMed announced the closing of a new fund for life science companies in the health sector. The fund acquires healthcare royalty streams and provides structured debt capital to healthcare...

BeNeLuxBelgiumNetherlandsLuxembourg

31.08.2011

Leiden/Stockholm – Dutch Pharming Group NV and Swedish specialist for rare diseases Orphan Biovitrum AB, have launched their recombinant C1 inhibitor Ruconest® in the Netherlands. The launch of the treatment for patients...

BeNeLuxBelgiumNetherlandsLuxembourg

22.08.2011

Leuven – ThromboGenics NV presented promising results of its Ocriplasmin Phase III clinical program at the Annual Meeting of the American Society of Retina Specialists (ASRS). „We remain on track to make regulatory filings for...

BeNeLuxBelgiumNetherlandsLuxembourg

18.08.2011

Liège – A Belgian research team from the University of Liège’s GIGA-Research centre has discovered an unexpected mode of action for the vaccine adjuvant alum. The team discovered that when a vaccine containing alum is injected...

BeNeLuxBelgiumNetherlandsLuxembourg

16.08.2011

Amsterdam – Dutch molecular diagnostics specialist Agendia B.V. postponed its initial public offering in June because of volatile market conditions, revealing that the financing environment for bio­tech firms remains tough....

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2011

Dutch gene therapy specialist Amsterdam Molecular Therapeutics BV (AMT) has filed a re-examination request for its lead product Glybera. At the end of June, EMA's CHMP recommended against approval of the product to treat...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Ghent – The Flanders Institute for Biotechnology VIB will receive EUR3m from the European Commission for the recruitment and training of promising international scientists in the life sciences. This will allow VIB to further...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Brussels – Belgian specialist for regenerative medicine TiGenix NV has raised EUR15.2m through the sale of 15.2 million shares at EUR1/share in a rights issue. Existing shareholders, who were eligible to purchase one share for...

Displaying results 31 to 40 out of 304

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/3/article/triple-play-ends.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3022.0%
  • GW PHARMACEUTICALS (UK)426.00 GBP654.0%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.14 EUR-70.6%

No liability assumed, Date: 29.07.2014


Current issue

All issues

Product of the week

Products